Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review

I Monsef, C Doree, EM Wood… - Cochrane Database …, 2020 - cochranelibrary.com
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …

COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes

D Focosi, M Franchini, L Pirofski… - Clinical microbiology …, 2022 - Am Soc Microbiol
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

Clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 convalescent plasma

LJ Estcourt, CS Cohn, MB Pagano… - Annals of internal …, 2022 - acpjournals.org
Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a
potential treatment of COVID-19. However, meta-analysis data and recommendations are …

Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real-world cohort of outpatients with COVID-19 at high risk of progression: the PISA …

G Tiseo, C Barbieri, V Galfo, S Occhineri… - Infectious Diseases and …, 2023 - Springer
Introduction Different antivirals are available for the treatment of outpatients with COVID-19.
Our aim was to describe a real-world experience of outpatient management of COVID-19 …

[HTML][HTML] Rates among hospitalized patients with COVID-19 treated with convalescent plasma: a systematic review and meta-analysis

JW Senefeld, EK Gorman, PW Johnson, ME Moir… - … : Innovations, Quality & …, 2023 - Elsevier
Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma

Q Dragotakes, PW Johnson, MR Buras… - Proceedings of the …, 2024 - pnas.org
In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent
plasma (CCP) to treat hospitalized patients. Over 500,000 patients were treated with CCP …

[HTML][HTML] Caring for older adults during the COVID-19 pandemic

V Prendki, G Tiseo, M Falcone - Clinical Microbiology and Infection, 2022 - Elsevier
Background Elderly patients represent a high-risk group with increased risk of death from
COVID-19. Despite the number of published studies, several unmet needs in care for older …

Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy

A Casadevall, MJ Joyner, LA Pirofski… - Expert review of …, 2023 - Taylor & Francis
Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis on randomized controlled trials

C Filippatos, I Ntanasis-Stathopoulos, K Sekeri… - Viruses, 2023 - mdpi.com
Background: While passive immunotherapy has been considered beneficial for patients with
severe respiratory viral infections, the treatment of COVID-19 cases with convalescent …

Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis

J Deng, K Heybati, HB Ramaraju, F Zhou, D Rayner… - Infection, 2023 - Springer
Purpose To assess and compare the relative efficacy and safety of anti-SARS-CoV-2
antibody regimens for COVID-19. Methods This systematic review and random-effects …